Further testing of this delivery system is needed in other rodent models of cardiovascular diseases, including hypertension, myocardial infarction, ischemia-reperfusion injury, and also other modes of alginate-CGRP microcapsules delivery is needed to verify in these cardiac diseases. This evidence concerns the gene CALCA and Hypertension.